The Indian pharmaceutical Firm Granules built a packaging facility in Virginia, the US, to boost the biopharma supply chain and expand the state’s capacity to package critical pharmaceuticals. The facility was formally launched by Taranjit Singh Sandhu, the Indian ambassador to the United States.
Granules has made about USD 100 million in investments in the country, according to Dr. Krishna Prasad Chigurupati, the founder, chairman, and managing director of the company. One of the first pharmaceutical businesses from India to receive an FDA licence for exporting to the US was the corporation.
He added that the company also has a group of 30 scientists for research and development. He said the vast majority of our approximately 200 employees in Virginia are first-generation Indians.
According to Chigurupati, Granules India Ltd. manufactures some of the most well-known drugs, including paracetamol. Billion people all across the world benefit greatly from these.
“Granules’ availability of “Made in India” medications at US dollar prices makes me delighted. The collaboration between the US and India on universal healthcare is ideal in this situation!” Ambassador Sandhu tweeted about his visit to the facility in Virginia.
In Sandhu’s opinion, one of the cornerstones of India-US bilateral relations is healthcare. He said, “In the early days of the COVID pandemic, India gave crucial medications and diagnostic kits to the United States,” noting that the US had assisted us during the second wave of the epidemic.
He emphasized that COVID-19 has shown the value of robust and long-lasting supply chains, especially in the context of a sector as significant as the Indian pharmaceutical industry.
India has the most plants outside of the US with FDA approval, according to Sandhu.
Our pharmaceutical and life sciences companies are also setting up manufacturing facilities in the US to reduce the cost and increase the accessibility of pharmaceuticals.
“We are working with the US Government to strengthen this supply chain and to ensure that key APIs and KSMs, aside from completed pharmaceuticals, are available to partner countries,” the Indian delegate stated.
One aspect of the expanding India-US economic story, according to him, is the success of the health partnership. The two nations’ rising trade, which will reach USD 191 billion in 2022, is said to be a major component of it.
Due to Indian firms like Granules, the US economy’s value and competitiveness have improved, and two-way investments are at an all-time high. According to a recent count, more than 200 Indian companies are present in the US and have made investments totaling more than $200 billion in practically all 50 states, according to Sandhu.
Granules India Ltd. received praise from Select USA, a US Department of Commerce-run organisation that promotes business investment that generates jobs in the country, for the opening of its new facility in Virginia.
The new plant will enhance the biopharmaceutical supply chain by increasing Virginia’s capacity to package necessary medications, said Atul Keshap, executive director of the US-India Business Council.
Read also-Prime Minister Modi says Indian pharma can be a $10 trillion market
